Molecular biological analysis for apoptosis induction and variation of cytoskeltons ＆ adhesion molecules in malignant melanoma

• Project/Area Number: 12670815
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Dermatology
• Research Institution: Gifu University
• Principal Investigator: TAKAGI Hajime School of Medicine Dept. Dermatol., Gifu University, Associate Prof., 医学部, 助教授 (70226752)
• Co-Investigator(Kenkyū-buntansha): IZUMI Tomoko School of Medicine Dept. Dermatol., Gifu University, Instructor, 医学部, 助手 (70324291) ; ICHIKI Yoshiro School of Medicine Dept. Dermatol., Gifu University, Assistant Prof., 医学部・附属病院, 講師 (30223093)
• Project Period (FY): 2000 – 2001
• Project Status: Completed (Fiscal Year 2001)
• Budget Amount: ¥4,000,000 (Direct Cost: ¥4,000,000); Fiscal Year 2001: ¥600,000 (Direct Cost: ¥600,000); Fiscal Year 2000: ¥3,400,000 (Direct Cost: ¥3,400,000)
• Keywords: apoptosis / cytoskeltons / adhesion molecules / 悪性黒色腫 / 抗腫瘍剤

Research Abstract

Basic research
1. Immunohistochemically we confirmed sequential bioimmunochemotherapy induced apoptosis for mouse melanoma cells. 2. We checked drug sensitivity of cultured human melanoma cells by FACScan. 3. Variation of cytoskelton, especially vimentin, were examined with immunofluorescent technique. But analysis was not enough, because of technical trouble. 4. Animal experiments were not done. We did not prepare to a favorable environment. 5. We compared extent of multidrug-resistance-associated protein between before and after chemotherapy. 6. We have been trying establish cell line of drug resistant melanoma cells.
Clinical research
1. We refer to the apoptosis cells, apoptosis- related gene/protein, and adhesion molecules by melanoma patients specimens immunohistochemically. 2. We measured melanoma inhibitory activity by ELISA method, and checked with association of the value and clinical course. 3. We evaluated of combination chemotherapy (DAC-Tam) for advanced malignant melanoma.
Summary
We cannot show enough results in this periods, but we got some promising products. We will keep this projects going on some experiments.

Research Products

• [Publications] H.Kubo et al.: "Sequential chemoimmuno therapy with cisplatin, interferon-β and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice"Melanoma Research. 10. 223-229 (2000)
  • Description: 「研究成果報告書概要(和文)」より
• [Publications] 神谷秀喜他: "進行期悪性黒色腫に対するDAC-Tam 療法の使用経験"西日皮膚. 63. 561-568 (2001)
  • Description: 「研究成果報告書概要(和文)」より
• [Publications] Kubo H, Matsumoto K, Funahashi M, Takagi H, Kitajima Y, Taniguchi S and Saida T: "Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in cyngeneic mice"Melanoma Research. 10. 223-229 (2000)
  • Description: 「研究成果報告書概要(欧文)」より
• [Publications] Kamiya H, Kanoh H, Ichihashi N, Ichiki Y, Takagi H, and Kitajima Y: "Evaluations of combination chemotherapy (DAC-Tam) for advanced malignant melanoma"Nishinihon J Dermatol. 63. 561-568 (2002)
  • Description: 「研究成果報告書概要(欧文)」より